We were recently approached by a clinical-stage biotech client to investigate one of their lead compounds used to treat COPD. Specifically, we wanted to know whether this compound would have any activity against SARS-CoV-2.
BioSymetrics Mechanism of Action Prediction Platform framework will be put to work both in prioritizing chemical libraries and in predicting mechanism for identified compounds.
Per the three COVID-19 research initiatives announced by the SCN in the post below, we will be working with William Stanford, Amy Wong, Molly Shoichet, Stephen Juvet, Samira Mubareka, Scott Gray-Own, and Mitchel Sabloff as a component of their research.
We will also have the opportunity to screen one of our own pre-clinical leads.